Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03621176
Other study ID # HBCKD
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2018
Est. completion date February 14, 2019

Study information

Verified date February 2019
Source Cardenal Herrera University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A home-based exercise program will be implemented in three different groups of participants: advanced chronic kidney disease, end-stage renal disease in substitutive treatment hemodialysis or peritoneal dialysis. Participants will be evaluated before the program, after 3 months and after 6 months from the starting of the program. During the first 3 months the researcher will phone them weekly to reinforce the exercise habit, and during the last three months, there will be no reinforcement. Assessment will include strength, functional capacity, health-related quality of life and depressive symptoms.


Description:

Three groups of participants (advanced chronic disease not yet in substitutive treatment, end-stage renal disease patients in hemodialysis and end-stage renal disease patients in peritoneal dialysis) will enter the study. The intervention will consist of a home-based exercise program. They will be provided with a booklet and the researcher will explain personally each of the exercises to the participants. Progression will be encouraged so that the participants should find the sessions 'somewhat hard' according to the rate of perceived exertion. Reinforcement will be high during the first 3 months (weekly phone calls, visits to the nephrology department) and none during the last 3 months. Assessment will be undertaken at three-time points: baseline, after 3 months of high reinforcement and after 3 more months of no reinforcement at all.

Assessment will include strength, functional capacity, health-related quality of life, cognitive state and depressive symptoms.

The aim of the study is to assess the effectiveness of home-based exercise to improve strength, physical function, health-related quality of life, cognitive state and depressive symptoms in advanced chronic kidney disease and end-stage renal disease (hemodialysis and peritoneal dialysis). We also aim at describing all these variables in the three different groups of patients. Adherence and satisfaction with the exercise program will be recorded at the end of the study.

Additionally, interobserver reliability will be calculated, so as reliability intraobserver in different measurement conditions (dialysis vs non-dialysis days).


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date February 14, 2019
Est. primary completion date January 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- At least 3 months in hemodialysis treatment

- Clinically stable

Exclusion Criteria:

- Recent cardiac events (less than 3 months)

- Unable to exercise

Study Design


Intervention

Other:
Home-based exercise
A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity

Locations

Country Name City State
Spain Hospital de Terrassa Terrassa Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Cardenal Herrera University Consorci Sanitari de Terrassa. Hospital de Terrassa

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Esteve Simo V, Junqué Jiménez A, Moreno Guzmán F, Carneiro Oliveira J, Fulquet Nicolas M, Pou Potau M, Saurina Sole A, Duarte Gallego V, Tapia Gonzalez I, Ramirez de Arellano M. Benefits of a low intensity exercise programme during haemodialysis sessions in elderly patients. Nefrologia. 2015;35(4):385-94. doi: 10.1016/j.nefro.2015.03.006. Epub 2015 Jul 21. English, Spanish. — View Citation

Segura-Ortí E, Martínez-Olmos FJ. Test-retest reliability and minimal detectable change scores for sit-to-stand-to-sit tests, the six-minute walk test, the one-leg heel-rise test, and handgrip strength in people undergoing hemodialysis. Phys Ther. 2011 Aug;91(8):1244-52. doi: 10.2522/ptj.20100141. Epub 2011 Jun 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline sit to stand 10 test at 12 and 24 weeks Sit to stand to sit test 10, time to perform 10 repetitions Baseline,1 week, non-dialysis day baseline,12 weeks, 24 weeks
Secondary Change from baseline Six-minute walking test at 12 and 24 weeks Distance covered in 6 minutes Baseline,1 week, non-dialysis day baseline,12 weeks, 24 weeks
Secondary Change from baseline STS-60 at 12 and 24 weeks Sit to stand to sit test 60, number of repetitions performed during 60 seconds Baseline,1 week, non-dialysis day baseline,12 weeks, 24 weeks
Secondary Change from baseline OLHR at 12 and 24 weeks One leg heel rise test, number of repetitions of heel rise to measure triceps strength Baseline,1 week, non-dialysis day baseline,12 weeks, 24 weeks
Secondary Change from baseline Handgrip strength (dynamometry) at 12 and 24 weeks Handgrip strength measured through a dynamometer Baseline,1 week, non-dialysis day baseline,12 weeks, 24 weeks
Secondary Change from baseline SPPB at 12 and 24 weeks Short physical performance battery, a combination of walking speed, STS-5 and balance Baseline,1 week, non-dialysis day baseline,12 weeks, 24 weeks
Secondary Change from baseline OLST at 12 and 24 weeks One-leg stand test, time to keep the balance in one leg Baseline,1 week, non-dialysis day baseline,12 weeks, 24 weeks
Secondary Change from baseline TUG at 12 and 24 weeks Timed up and go test, time to stand up from a chair, walk 3m, turn around and sit back again Baseline,1 week, non-dialysis day baseline,12 weeks, 24 weeks
Secondary Change from baseline Albumin at 12 and 24 weeks Serum albumin in blood for dialysis patients Baseline,12 weeks, 24 weeks
Secondary Change from baseline Health-related quality of life measured through the Euro quality of life questionnaire, 5 dimensions, at 12 and 24 weeks Euroquol 5D questionnaire, scale 0 (worst health) to 100 (best health). 5 Dimensions include mobility, personal care, activities of daily living, pain, and anxiety/depression Baseline,12 weeks, 24 weeks
Secondary Change from baseline Beck depression inventory at 12 and 24 weeks Questionnaire to measure depressive symptoms. Range from 0 (normal) to 63 (worst depression) Baseline,12 weeks, 24 weeks
Secondary Change from baseline Human activity profile at 12 and 24 weeks Human activity profile Questionnaire to measure physical activity. Higher score represents higher activity. Measures of average and maximal activity scores are reported. Average activity scores bellow 53 are considered impaired; between 53 and 74 are considered moderately active and above 74 are considered active. Baseline,12 weeks, 24 weeks
Secondary Change from baseline Physical Activity Scale for the elderly at 12 and 24 weeks Questionnaire to measure physical activity. Higher scores represent higher activity. Baseline,12 weeks, 24 weeks
Secondary Adherence Sessions performed/offered x 100 12 weeks, 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4